Variant position: 880 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 2871 The length of the canonical sequence.
Location on the sequence:
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human GRCEININGATLKSQCCSSL GAAWGSPCTLCQVDPICGKGY
Mouse GRCEININGATLKSECCSSL GAAWGSPCTICQLDPICGKGF
Pig GRCEININGATLKSQCCSSL GAAWGSPCTPCQVDPICGKGY
Bovine GRCEININGATLKSQCCSSL GAAWGSPCTPCQVDPICGKGY
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Mutation screening of the fibrillin-1 (FBN1) gene in 76 unrelated patients with Marfan syndrome or Marfanoid features leads to the identification of 11 novel and three previously reported mutations.
Rommel K.; Karck M.; Haverich A.; Schmidtke J.; Arslan-Kirchner M.;
Hum. Mutat. 20:406-407(2002)
Cited for: VARIANTS MFS 429-ARG--HIS-2871 DEL; ILE-449; SER-880; CYS-1101; TYR-1806; ILE-1908; ASP-1919 AND ARG-2251;
FBN1 mutation screening of patients with Marfan syndrome and related disorders: detection of 46 novel FBN1 mutations.
Attanasio M.; Lapini I.; Evangelisti L.; Lucarini L.; Giusti B.; Porciani M.; Fattori R.; Anichini C.; Abbate R.; Gensini G.; Pepe G.;
Clin. Genet. 74:39-46(2008)
Cited for: VARIANTS MFS TYR-123; SER-136; SER-177; TYR-177; SER-214; 348-GLN--HIS-2871 DEL; 429-ARG--HIS-2871 DEL; ARG-488; TYR-576; ARG-582; PHE-623; CYS-635; TYR-684; CYS-721; ARG-816; SER-880; GLU-884; TYR-1008; SER-1042; 1125-ARG--HIS-2871 DEL; 1136-TYR--HIS-2871 DEL; TRP-1182; TYR-1265; ARG-1320; 1534-CYS--HIS-2871 DEL; 1539-ARG--HIS-2871 DEL; 1541-ARG--HIS-2871 DEL; GLY-1631; ARG-1672; TYR-1672; GLY-1674; 1735-GLN--HIS-2871 DEL; LYS-1811; ARG-1847; TYR-1860; LYS-1894; TYR-1900; GLY-1934; TRP-1977; 2057-ARG--HIS-2871 DEL; 2062-TYR--HIS-2871 DEL; 2064-LYS--HIS-2871 DEL; TYR-2084; LYS-2130; ARG-2221; TYR-2232; THR-2269; THR-2284; TYR-2470; PRO-2561; LYS-2570; ARG-2577 AND 2694-ARG--HIS-2871 DEL; VARIANTS PRO-39; ARG-937; ALA-1020; TRP-2726 AND 2774-LYS--HIS-2871 DEL;
Exon 47 skipping of fibrillin-1 leads preferentially to cardiovascular defects in patients with thoracic aortic aneurysms and dissections.
Wang W.J.; Han P.; Zheng J.; Hu F.Y.; Zhu Y.; Xie J.S.; Guo J.; Zhang Z.; Dong J.; Zheng G.Y.; Cao H.; Liu T.S.; Fu Q.; Sun L.; Yang B.B.; Tian X.L.;
J. Mol. Med. 91:37-47(2013)
Cited for: VARIANTS MFS GLU-55; GLN-219; SER-699; SER-880; TYR-908; ARG-1117; ALA-1199; 1539-ARG--HIS-2871 DEL; GLY-1642; ARG-1865; 2081-GLN--HIS-2871 DEL AND 2220-ARG--HIS-2871 DEL;
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.